GenFleet Therapeutics (Shanghai) Inc. (Stock Code: 2595) held an extraordinary general meeting (EGM) on February 9, 2026. According to the announcement, the EGM was legally and validly convened at 10:00 a.m. in Shanghai. All directors either attended in person or participated electronically.

All seven special resolutions presented at the EGM were passed by the required threshold of at least two-thirds of the votes cast. These resolutions included the adoption of an H Share Option Scheme, an H Share Incentive Scheme, their respective limits and authorization details, as well as the general mandate to repurchase H Shares. Poll results indicated approval percentages exceeding the two-thirds requirement in every case.

A key development approved by the shareholders was the abolishment of the Supervisory Committee and corresponding amendments to the company’s Articles of Association. As a result, effective from February 9, 2026, the Supervisory Committee will no longer be in place, and current members will cease to hold office as Supervisors. The amended Articles of Association, finalized on that date, were published on the official websites of GenFleet Therapeutics (Shanghai) Inc. and the Hong Kong Stock Exchange.